Lipocine Q3 2026 earnings

LPCN · 2026-11-05 09:35 during market hours ET · 8-K on SEC

Net loss narrowed to $0.7 million, and revenue surged to $2.3 million driven by a new license agreement, while cash reserves increased to $21.5 million.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$2.29M+1,890%+1,104%Ex. 99.1, income statement
EPS (GAAP)($0.08)+86%-75%Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
License and collaboration revenue$2.10M+Infinity92%New revenue stream in 2026
Royalty revenue (TLANDO)$0.19M+66%8%Consistent with prior quarter

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $3.16M (+5%)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge not stated in the 8-K

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$2.59M$4.98M$5.21M-50%
Total unrestricted cash, cash equivalents and marketable investment securities$21.50M$23.30M$14.90M-8%
License fee and royalties receivable$0.69M$0.19M$1.15M+262%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Revenue jumped to $2.3 million driven by a $2.1 million license and collaboration agreement, offsetting a slight decline in TLANDO royalty revenue to $190,000.
  • EPS story The EPS improvement to ($0.08) came from a significantly narrower net loss driven by the new license revenue and lower operating expenses.
  • One-off check not stated in the 8-K

The good

  • License revenue of $2.1 million established a new revenue stream.
  • Net loss narrowed to $0.7 million from $3.2 million YoY.
  • Cash balance increased to $21.5 million from $14.9 million YoY.

The bad

  • R&D expenses increased to $2.1 million YoY due to higher costs for LPCN 1154 studies.
  • G&A expenses increased to $1.1 million YoY driven by higher legal and personnel costs.

The ugly

  • none

Open questions

  • The release does not disclose the terms of the new license and collaboration agreement.
  • The release does not disclose the specific amount of the $2.1 million license revenue recognized in Q3 2025.
Full release

Lipocine (LPCN) earnings release, November 5, 2026

Lipocine Inc. (LPCN) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Lipocine

Announces Financial Results for the Third Quarter of 2026

SALT

LAKE CITY,

November 5, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the third quarter ended September 30, 2026 and provided a corporate update.

Recent

Developments and Corporate Update

LPCN

1154 (BRLIZIO™) for Postpartum Depression (PPD)

In

September 2026, Lipocine announced the initiation of the BLOOM (Brexanolone Lifting Outcomes of Moms) study. The Phase 3 placebo-controlled outpatient study is expected to enroll approximately 120 participants with PPD and is designed to generate prospective efficacy and safety evidence to support a potential New Drug Application (NDA) under the 505(b)(2) pathway. Feedback from a recent meeting with the FDA, including the necessity of a positive and well-controlled Phase 3 trial, together with learnings from the prior Phase 3 trial, are incorporated into the BLOOM study design. Further, feedback from the FDA acknowledged that the NDA submission package presented to FDA appears complete to support 505(b)(2) NDA submission with the exception of the need for a single positive and well controlled Phase 3 trial.

Other

Neuroactive Steroid Programs

TLANDO®

Third

Quarter Ended September 30, 2026 Financial Results

As of September 30, 2026, Lipocine had $21.5 million of unrestricted cash, cash equivalents and marketable investment securities, compared to $14.9 million at December 31, 2025. As of November 4, 2026, the Company had approximately $28.5 million of unrestricted cash, cash equivalents and marketable investment securities (unaudited).

Lipocine reported a net loss of $0.7 million, or ($0.08) per diluted share, for the quarter ended September 30, 2026, compared to a net loss of

$3.2 million, or ($0.59) per diluted share, for the quarter ended September 30, 2025.

Lipocine recognized total revenue of $2.3 million during the quarter ended September 30, 2026, compared to $115,000 during the quarter ended September 30, 2025. Revenue for the third quarter of 2026 consisted of license and collaboration revenue of $2.1 million and royalty revenue from

TLANDO sales of $190,000. Revenue for the third quarter of 2025 consisted entirely of royalty revenue from TLANDO sales.

Research and development expenses were $2.1 million and $2.7 million, respectively, for the quarters ended September 30, 2026 and 2025. The decrease primarily reflects lower costs related to the LPCN 2401 study, which was placed on hold in 2025, and lower LPCN 1154 clinical costs in

2026 compared with costs incurred for the prior Phase 3 study during the third quarter of 2025, partially offset by an increase in personnel costs.

General and administrative expenses were $1.1 million and $0.8 million, respectively, for the quarters ended September 30, 2026 and 2025. The increase primarily reflects higher personnel costs and higher legal fees related to protecting the Company’s intellectual property and promoting its corporate strategy.

Interest and investment income was $0.2 million for each of the quarters ended September 30, 2026 and 2025.

Nine

Months Ended September 30, 2026 Financial Results

Lipocine reported a net loss of $7.0 million, or ($0.90) per diluted share, for the nine months ended September 30, 2026, compared to a net loss of $7.3 million, or ($1.35) per diluted share, for the nine months ended September 30, 2025.

Lipocine recognized revenue of $2.6 million and $831,000 during the nine months ended September 30, 2026 and 2025, respectively. Revenue for the

2026 period consisted of license and collaboration revenue of $2.1 million and royalty revenue from TLANDO sales of $500,000. Revenue for the 2025 period consisted of license revenue of $500,000 and royalty revenue from TLANDO sales of $331,000.

Research and development expenses were $6.9 million and $5.9 million, respectively, for the nine-month periods ended September 30, 2026 and 2025.

The increase primarily reflects higher costs related to LPCN 1154 studies and other clinical trial costs, as well as an increase in personnel expense.

General and administrative expenses were $3.3 million and $2.8 million, respectively, for the nine-month periods ended September 30, 2026 and

2025. The increase primarily reflects higher legal fees related to protecting the Company’s intellectual property and promoting its corporate strategy, as well as an increase in personnel expense.

Interest and investment income was $0.6 million for each of the nine-month periods ended September 30, 2026 and 2025.

For further detail on Lipocine’s financial results for the three and nine months ended September 30, 2026, refer to the Company’s

Form 10-Q filed with the SEC.

About

Lipocine

Lipocine is a biopharmaceutical company developing oral therapeutics using its proprietary drug-delivery technology platform. The Company advances product candidates addressing significant unmet medical needs and explores partnerships to support their development and commercialization.

Lipocine’s development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder,

LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com....ard

Looking Statements

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenues:
License revenue2,100,000$-2,100,000500,000
Royalty revenue190,072114,574499,568331,287
Total revenues2,290,072114,5742,599,568831,287
Operating expenses:
Research and development2,070,0332,707,7776,875,8165,906,118
General and administrative1,088,564767,8373,283,9872,780,747
Total operating expenses3,158,5973,475,61410,159,8038,686,865
Operating loss-868,525-3,361,040-7,560,235-7,855,578
Other income:
Interest and investment income202,333174,208599,754598,357
Total other income202,333174,208599,754598,357
Loss before income tax expense-666,192-3,186,832-6,960,481-7,257,221
Income tax expense-200-200
Net loss attributable to common shareholders Net loss attributable to common shareholders-666,192-3,186,832-6,960,681-7,257,421
Basic loss per share attributable to common stock-0.08-0.59-0.9-1.35
Weighted average common shares outstanding, basic8,244,5425,413,1497,757,4875,371,458
Diluted loss per share attributable to common stock-0.08-0.59-0.9-1.35
Weighted average common shares outstanding, diluted8,244,5425,413,1497,757,4875,371,458
Comprehensive loss:
Net loss-666,192-3,186,832-6,960,681-7,257,421
Net unrealized gain (loss) on marketable investment securities-13,1585,870-31,004-4,511
Comprehensive loss-679,350-3,180,962-6,991,685-7,261,932

Balance Sheet

September 30, — (Unaudited)

September 30, – 2026December 31, – 2025
Current assets:
Cash and cash equivalents2,594,1515,205,842
Marketable investment securities18,861,2979,724,545
Accrued interest income208,46214,189
License fee and royalties receivable690,0711,145,390
Prepaid and other current assets758,676787,600
Total current assets23,112,65716,877,566
Property and equipment, net of accumulated depreciation of $1,328,188 and $1,284,079 respectively60,184104,293
Other assets23,75323,753
Total assets23,196,59417,005,612
Current liabilities:
Accounts payable544,347971,822
Accrued expenses1,170,0991,236,374
Deferred revenue320,000320,000
Total current liabilities2,034,4462,528,196
Total liabilities2,034,4462,528,196
Stockholders’ equity:
Common stock, par value $0.0001 per share, 75,000,000 shares authorized; 8,245,798 and 6,158,779 issued and 8,245,462 and 6,158,443 outstanding, respectively9,1538,944
Additional paid-in capital237,577,314223,901,106
Treasury stock at cost, 336 shares-40,712-40,712
Accumulated other comprehensive income-26,5594,445
Accumulated deficit-216,357,048-209,396,367
Total stockholders’ equity21,162,14814,477,416
Total liabilities and stockholders’ equity23,196,59417,005,612

This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995 and include statements that are not historical facts regarding our development of our products and product candidates and related efforts with the FDA, including the design, planned enrollment, timing and potential outcomes of the BLOOM study; the sufficiency of existing financial and operational resources to execute the study; expected average monthly cash use, study expenditures and cash needs; the timing of clinical trials and regulatory submissions; the timing of anticipated commercial launches of licensed products; the potential uses and benefits of our products and product candidates; the commercial potential for our product candidates; and potential strategic partnerships and other opportunities. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of an NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, variability in enrollment and site performance, study costs exceeding current estimates, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

SOURCE

Lipocine Inc.

For further information:

Krista

Fogarty

Phone:

(801) 994-7383 kf@lipocine.com

Investors:

PJ

Kelleher

Phone:

(617) 430-7579 pkelleher@lifesciadvisors.com

LIPOCINE

INC. AND SUBSIDIARIES

Condensed

Consolidated Balance Sheets

(Unaudited)

LIPOCINE

INC. AND SUBSIDIARIES

Condensed

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.